中国经济网北京11月19日讯 汇宇制药(688553.SH)今日收报20.60元，跌幅5.24%。目前该股处于破 发状态。 2021年10月26日，汇宇制药在上交所科创板上市，公开发行股票6360.00万股，发行价格为38.87元/ 股，保荐机构、主承销商为中信建投证券，保荐代表人为杨泉、田斌，联席主承销商为国都证券。 汇宇制药发行费用合计1.11亿元，其中中信建投证券、国都证券获得承销费9887.48万元。 （责任编辑：何潇） 上市当日，汇宇制药盘中最高报42.59元，创上市以来股价最高点。 汇宇制药发行募集资金总额为24.72亿元，扣除发行费用后，募集资金净额为23.61亿元。汇宇制药 最终募集资金净额比原计划多4.53亿元。汇宇制药于2021年10月18日披露的招股书显示，公司拟募集资 金19.07亿元，分别用于汇宇欧盟标准注射剂产业化基地（二期）项目、汇宇创新药物研究院建设项 目、补充流动资金。 ...

格隆汇11月19日｜有投资者在互动平台向汇宇制药提问：相关媒体报道，公司在前段时间的进博会上， 与阿斯利康签订了战略合作框架协议。但公司在业绩说明会上表示，公司尚未与阿斯利康达成任何药物 研究合作。公司能具体说说双方之间的关系吗？ 汇宇制药回复称，公司与阿斯利康已签署战略合作框 架协议，该协议不涉及具体药物研究合作内容，不会对公司经营产生重大影响，该事项未达披露标准， 因此公司未进行披露。未来，公司期待与阿斯利康进行药物研究等更多合作，如后续合作预计将对公司 经营产生重大影响，公司将严格按照监管规定，及时履行信息披露义务并发布公告。 ...

中国经济网北京11月19日讯汇宇制药(688553.SH)今日收报20.60元，跌幅5.24%。目前该股处于破发状 态。 2021年10月26日，汇宇制药在上交所科创板上市，公开发行股票6360.00万股，发行价格为38.87元/股， 保荐机构、主承销商为中信建投（601066）证券，保荐代表人为杨泉、田斌，联席主承销商为国都证 券。 汇宇制药发行募集资金总额为24.72亿元，扣除发行费用后，募集资金净额为23.61亿元。汇宇制药最终 募集资金净额比原计划多4.53亿元。汇宇制药于2021年10月18日披露的招股书显示，公司拟募集资金 19.07亿元，分别用于汇宇欧盟标准注射剂产业化基地(二期)项目、汇宇创新药物研究院建设项目、补充 流动资金。 汇宇制药发行费用合计1.11亿元，其中中信建投证券、国都证券获得承销费9887.48万元。 上市当日，汇宇制药盘中最高报42.59元，创上市以来股价最高点。 ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 1.44% on November 19, with Hainan Haiyao leading the drop [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Shanhe Pharmaceutical (300452) with a closing price of 15.07, up 9.04% and a trading volume of 390,200 shares, totaling 586 million yuan [1] - ST Suhao (600200) closed at 1.02, up 5.15% with a trading volume of 429,200 shares [1] - ST Jingfeng (000908) closed at 66.8, up 5.02% with a trading volume of 354,800 shares [1] - Major decliners included: - Muan Nanhai (000566) with a closing price of 7.20, down 10.00% and a trading volume of 2,192,500 shares, totaling 1.625 billion yuan [2] - Sitaili (603520) closed at 10.66, down 6.74% with a trading volume of 315,600 shares [2] - Yatai Pharmaceutical (002370) closed at 7.79, down 6.59% with a trading volume of 1,044,700 shares [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 2.278 billion yuan from institutional investors, while retail investors contributed a net inflow of 2.139 billion yuan [2] - The top stocks by net inflow from institutional investors included: - Changshan Pharmaceutical (300255) with a net inflow of 71.90 million yuan, accounting for 6.20% of total inflow [3] - Xingqi Eye Medicine (300573) with a net inflow of 70.33 million yuan, representing 12.29% [3] - Shanhe Pharmaceutical (300452) with a net inflow of 68.13 million yuan, making up 11.62% [3]

证券代码：688553 证券简称：汇宇制药 公告编号：2025-090 四川汇宇制药股份有限公司 关于自愿披露公司产品获得境外上市许可的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川汇宇制药股份有限公司（以下简称"公司"）子公司 Seacross Pharmaceuticals Ltd.于近期分别收到巴基斯坦药品监督管理局、英国药品和健康 产品管理局和北马其顿药品和医疗设备管理局核准签发的公司产品普乐沙福注 射液、注射用塞替派、注射用阿扎胞苷、注射用唑来膦酸浓溶液、唑来膦酸注射 液的上市许可。现将相关情况公告如下： 二、公司产品的其他相关情况 （一）普乐沙福注射液 普乐沙福注射液与粒细胞集落刺激因子（G-CSF）联用，适用于非霍奇金淋 巴瘤（NHL）和多发性骨髓瘤（MM）患者动员造血干细胞（HSC）进入外周血， 以便于完成 HSC 采集与自体移植。 公司产品普乐沙福注射液研发成功后已进行了多国注册申报，分别已在中国、 英国、法国、德国、荷兰、秘鲁、巴基斯坦等 30 个国家获得上市许可。截至目 前，公司已分别在包 ...

Core Viewpoint - Seacross Pharmaceuticals Ltd., a subsidiary of the company, has received marketing approvals for several products from regulatory authorities in Pakistan, the UK, and North Macedonia [1] Group 1 - The approved products include Plasmapheresis Injection, Injection of Setipiprant, Injection of Azacitidine, Concentrated Solution of Zoledronic Acid, and Zoledronic Acid Injection [1]

Core Viewpoint - Seacross Pharmaceuticals Ltd., a subsidiary of 汇宇制药 (688553.SH), has received marketing approvals for several products from regulatory authorities in Pakistan, the UK, and North Macedonia [1] Group 1: Regulatory Approvals - The company has obtained marketing licenses for the following products: - 普乐沙福注射液 (Plerixafor Injection) - 注射用塞替派 (Injectable Setipiprant) - 注射用阿扎胞苷 (Injectable Azacitidine) - 注射用唑来膦酸浓溶液 (Injectable Zoledronic Acid Concentrate) - 唑来膦酸注射液 (Zoledronic Acid Injection) from the respective drug regulatory agencies [1]

11月19日，汇宇制药跌5.2%，截至发稿，报20.61元/股，成交5827.48万元，换手率0.80%，总市值87.30 亿元。 资料显示，四川汇宇制药股份有限公司位于四川省内江市市中区汉阳路333号3幢，成立日期2010年10月 12日，上市日期2021年10月26日，公司主营业务涉及肿瘤领域药物和复杂注射剂药物的研发、生产和国 内外销售。主营业务收入构成为：药品销售97.27%，技术服务1.66%，其他1.07%。 从汇宇制药十大流通股东角度 数据显示，平安基金旗下1只基金位居汇宇制药十大流通股东。平安医疗健康混合A（003032）三季度 新进十大流通股东，持有股数683.78万股，占流通股的比例为1.99%。根据测算，今日浮亏损失约 772.68万元。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 平安医疗健康混合A（003032）成立日期2017年11月24日，最新规模20.28亿。今年以来收益63.9%，同 类排名315/8138；近一年 ...

Group 1 - The core point of the article is that Huayu Pharmaceutical has received approval from the National Medical Products Administration for its product, Etoposide Injection, which is a significant regulatory milestone for the company [1] - As of the latest report, Huayu Pharmaceutical's revenue composition for the year 2024 is heavily weighted towards pharmaceuticals, with 99.18% of revenue coming from this sector, indicating a strong focus on its core business [2] - The current market capitalization of Huayu Pharmaceutical is 9.1 billion yuan, reflecting its position in the market [3]

Core Viewpoint - The company has received approval from the National Medical Products Administration for its product, Etoposide Injection, which is indicated for several types of cancer [1] Group 1: Product Approval - The company has been granted a drug registration certificate for Etoposide Injection [1] - Etoposide Injection is primarily indicated for small cell lung cancer, malignant lymphoma, malignant germ cell tumors, leukemia, neuroblastoma, rhabdomyosarcoma, ovarian cancer, non-small cell lung cancer, gastric cancer, and esophageal cancer [1]